2007
Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling.
Muinck ED, Nagy N, Tirziu D, Murakami M, Gurusamy N, Goswami SK, Ghatpande S, Engelman RM, Simons M, Das DK. Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling. Antioxidants & Redox Signaling 2007, 9: 437-45. PMID: 17280485, DOI: 10.1089/ars.2006.1501.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsAntimicrobial Cationic PeptidesApoptosisBlotting, WesternCell LineGenetic TherapyHumansHypoxia-Inducible Factor 1, alpha SubunitIn Situ Nick-End LabelingMaleMalondialdehydeMiceMice, Inbred C57BLMutationMyocardial Reperfusion InjuryReactive Oxygen SpeciesReceptor, Fibroblast Growth Factor, Type 1Signal TransductionTime FactorsConceptsCoronary flowMyocardial ischemic reperfusion injuryMyocardial ischemia-reperfusion injuryEmpty vectorIschemia-reperfusion injuryIschemic reperfusion injuryLVdP/dtVentricular developed pressureMin of ischemiaBaseline coronary flowMyocardial infarct sizeGene therapyReperfusion injuryCardioprotective abilityInfarct sizeDeveloped pressureHIF-1alpha proteinTTC stainingAortic flowHeart rateCardiomyocyte apoptosisEx vivoCardioprotectionHIF1alpha stabilizationHemodynamics
2005
Angiogenesis in the human heart: Gene and cell therapy
Tirziu D, Simons M. Angiogenesis in the human heart: Gene and cell therapy. Angiogenesis 2005, 8: 241-251. PMID: 16308736, DOI: 10.1007/s10456-005-9011-z.Peer-Reviewed Original ResearchConceptsNew vessel growthCell therapyPeripheral arterial diseaseVessel growthBest cell typeStimulation of angiogenesisMechanism of actionArterial diseasePatient selectionClinical trialsBlood supplyIschemic tissueIschemic diseasesNew therapiesTherapyGrowth factorHuman heartDiseaseCell typesAngiogenesisMain biological processesPatientsMultiple questionsTrials